| Title |
Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia
|
|---|---|
| Published in |
Advances in Therapy, July 2017
|
| DOI | 10.1007/s12325-017-0586-8 |
| Pubmed ID | |
| Authors |
Franck Boccara, Ricardo Dent, Luis Ruilope, Paul Valensi |
| Abstract |
Suboptimal drug adherence represents a major challenge to effective primary and secondary prevention of cardiovascular disease. While adherence is influenced by multiple considerations, polypharmacy and dosing frequency appear to be rate-limiting factors in patient satisfaction and subsequent adherence. The cardiovascular and metabolic therapeutic areas have recently benefited from a number of advances in drug therapy, in particular protease proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and incretin-based therapies, respectively. These drugs are administered subcutaneously and offer efficacious treatment options with reduced dosing frequency. Whilst patients with diabetes and diabetologists are well initiated to injectable therapies, the cardiovascular therapeutic arena has traditionally been dominated by oral agents. It is therefore important to examine the practical aspects of treating patients with these new lipid-lowering agents, to ensure they are optimally deployed in everyday clinical practice. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 46 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 10 | 22% |
| Researcher | 8 | 17% |
| Other | 5 | 11% |
| Student > Ph. D. Student | 4 | 9% |
| Student > Postgraduate | 3 | 7% |
| Other | 4 | 9% |
| Unknown | 12 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 37% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 15% |
| Nursing and Health Professions | 5 | 11% |
| Agricultural and Biological Sciences | 3 | 7% |
| Immunology and Microbiology | 1 | 2% |
| Other | 1 | 2% |
| Unknown | 12 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 July 2017.
All research outputs
#18,562,247
of 22,990,068 outputs
Outputs from Advances in Therapy
#1,670
of 2,380 outputs
Outputs of similar age
#217,896
of 283,549 outputs
Outputs of similar age from Advances in Therapy
#31
of 40 outputs
Altmetric has tracked 22,990,068 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,380 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.4. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 283,549 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.